Beyond Psilocybin: Other Mushroom Alkaloids

Psilocybin and its active metabolite, psilocin, are the most well-known psychoactive compounds in magic mushrooms. They are the primary drivers of the psychedelic experience and the main analytes measured in lab tests for potency. However, they are not the only alkaloids present. Mushrooms from the *Psilocybe genus produce a range of other, structurally related compounds that exist in smaller quantities. These "minor" or "secondary" alkaloids are an emerging area of research, with many scientists speculating that they may play a crucial role in shaping the unique effects of different mushroom species and even different batches of the same species.

This concept is not new in the world of natural products. The cannabis industry has long discussed the "entourage effect," where minor cannabinoids (like CBG, CBN) and terpenes work synergistically with THC and CBD to produce nuanced effects. A similar principle may apply to psilocybin mushrooms. The presence of a complex suite of compounds, rather than just psilocybin alone, could explain why many users report that consuming whole mushrooms feels qualitatively different from consuming pure, synthetic psilocybin. The subtle variations in a mushroom’s chemical profile could be responsible for the reported differences between, for example, the experience from Psilocybe cubensis versus Psilocybe cyanescens.

What Are the Minor Mushroom Alkaloids?

Alkaloids are a class of naturally occurring chemical compounds that mostly contain basic nitrogen atoms. In plants and fungi, they often serve as defense mechanisms against herbivores. In humans, they can have pronounced physiological and psychological effects. While psilocybin is the most famous alkaloid in magic mushrooms, it’s technically a prodrug that the body converts into the primary active compound, psilocin. Alongside these two, researchers have identified several others.

The most notable minor alkaloids include:

• Baeocystin: A phosphorylated analogue of psilocin's methylated counterpart. It is a derivative of psilocybin, first isolated from *Psilocybe baeocystis. Early, unconfirmed bioassays from the 1960s suggested it might be psychoactive, but modern research has yet to definitively characterize its effects in humans. It is often found alongside psilocybin in many common mushroom species.
• Norbaeocystin: Another psilocybin derivative found in small quantities. Its pharmacology is largely unknown, and it is considered a minor component of the mushroom's total alkaloid profile.
• Norpsilocin: Discovered more recently, norpsilocin was identified in 2017. Lab studies suggest it may be an active psychedelic, interacting with the same serotonin receptors as psilocin. Its potency and contribution to the overall experience are still under investigation, but its presence further complicates the simple "psilocybin-equals-potency" equation.
• Aeruginascin: First isolated from the mushroom *Inocybe aeruginascens, this compound is structurally unique because it contains a trimethylammonium group. It is a structural analogue of a compound related to DMT, leading to much speculation about its potential effects.

Do These Alkaloids Change the Experience?

The central question is whether these minor alkaloids, present in small concentrations, actually modulate the psychedelic experience. The current scientific consensus is that psilocin is the primary driver of the psychoactive effects. However, the theory of an entourage effect in mushrooms, similar to what's observed in cannabis, is gaining traction. This theory proposes that the full spectrum of a mushroom’s chemical constituents work together to create an effect that is greater than the sum of its parts. For more detail on this concept, see our post explaining the mushroom entourage effect.

For example, some researchers speculate that the presence of aeruginascin may lead to a different kind of trip, one that is potentially less anxiogenic (anxiety-inducing). Some anecdotal reports connect mushroom species high in aeruginascin with lower instances of anxiety during the experience. This has not been proven in a clinical setting, but it points to a potential mechanism for the varied effects reported from different mushrooms. The different ratios of these compounds could explain why a strain like Golden Teacher is often described as having a more "spiritual" or "gentle" effect, while other strains are known for being more visual or potent, even when their primary psilocybin concentrations are similar.

Furthermore, the interactions between these compounds could be complex. One alkaloid might influence how quickly psilocybin is converted to psilocin, while another might compete for the same receptors in the brain, subtly altering the overall effect. This could impact everything from the speed of the onset to the qualitative nature of the visuals and the emotional tone of the experience. It also underscores why using whole-mushroom products may offer a different experience compared to isolates. While a pure psilocybin product provides a predictable dose, a whole-mushroom product, like those found in our capsules collection, contains the complete range of compounds native to the fungus.

Why Don't Lab Reports Test for Minor Alkaloids?

If these compounds are potentially important, why do standard lab reports—known as Certificates of Analysis (CofAs)—only test for psilocybin and psilocin? The answer lies in the practical challenges and priorities of commercial lab testing.

The primary reasons include:

• Lack of Certified Reference Materials: To accurately test for a chemical compound, laboratories need a highly purified and certified sample of that compound to calibrate their instruments. These are known as Certified Reference Materials (CRMs). CRMs for psilocybin and psilocin are available, but they are rare, expensive, and in some cases, non-existent for minor alkaloids like norpsilocin or aeruginascin. Without a reliable reference, labs cannot quantify these compounds with certainty.
• Cost and Complexity: Testing for a wider array of compounds requires more advanced and sensitive analytical techniques, such as Liquid Chromatography with tandem Mass Spectrometry (LC-MS/MS). This equipment is significantly more expensive to acquire and operate than the High-Performance Liquid Chromatography (HPLC) systems typically used for standard potency testing. For most product manufacturers, the cost of this expanded analysis is prohibitive.
• Focus on Dosing and Safety: The main goal of commercial potency testing is to ensure product consistency and consumer safety. Since psilocybin and psilocin are responsible for the vast majority of the psychoactive effects, quantifying them allows for accurate dosing. This is the most critical information for a consumer, whether they are microdosing or seeking a higher-dose experience.

As the industry matures, this may change. Increased research into the pharmacology of minor alkaloids could lead to the development of affordable CRMs and more accessible testing methods. For now, the focus remains on the two primary compounds that can be measured accurately and reliably. The potential influence of minor alkaloids remains an exciting frontier in mushroom science, promising a deeper understanding of the fungus's complex chemistry.